Amid uncertainty over how the Trump administration would approach mRNA COVID-19 vaccines for the upcoming respiratory virus season, the FDA has approved updated shots from Pfizer and Moderna. But ...

A slightly disappointing revenue outlook from Pfizer (PFE) was enough for its COVID-19 vaccine rivals Moderna (MRNA) and Novavax (NVAX) to trade lower on Tuesday, just as a major safety scare related ...

The Trump administration’s dramatic reworking of U.S. public-health agencies’ approach to vaccines is creating a difficult and unpredictable situation for drugmakers. Pfizer, in particular, could be ...

Parents in the United States who want to vaccinate their young children against Covid-19 may face a growing set of challenges this fall. The US Food and Drug Administration might not renew ...

Sept 3 (Reuters) - Pfizer (PFE.N), opens new tab and Moderna (MRNA.O), opens new tab on Wednesday defended their COVID-19 vaccines as having saved millions of lives worldwide, in separate responses to ...

In response to a call from President Donald Trump to make the positive impact of Covid-19 vaccines public, drug giant Pfizer posted a collection of more than 200 news releases and statements and 27 ...

The Food and Drug Administration may revoke authorization for Pfizer’s COVID-19 vaccine for healthy children under age 5, the pharmaceutical company confirmed, which would limit parents' vaccine ...

The U.S. Food and Drug Administration (FDA) may not renew the Emergency Use Authorization for the Pfizer-BioNTech COVID-19 vaccine for children under the age of five, the company said. The possible ...

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. Of 9,225 ...

PHILADELPHIA (WPVI) -- An estimated 28 million children across the U.S. would be eligible for COVID-19 vaccine shots if regulators give the green light, but it's a process that could take weeks.

Valneva has reported phase 2 data on the third booster dose of its Pfizer-partnered Lyme disease vaccine candidate, ticking off another task for a prospect that could reach regulatory review next year ...